Experimental Ebola vaccine protects monkeys for 10 months

[riky]

Experimental Ebola vaccine protects monkeys for 10 months

<p><a href="http://news.yahoo.com/experimental-ebola-vaccine-protects-monkeys-10-months-170719536--finance.html"><img src="http://l1.yimg.com/bt/api/res/1.2/HQnrxcrWdIfUJNQTxOposg--/YXBwaWQ9eW5ld3M7Zmk9ZmlsbDtoPTg2O3E9NzU7dz0xMzA-/http://media.zenfs.com/en_us/News/ap_webfeeds/ff62ef0237d608235f0f6a7067005c9e.jpg" width="130" height="86" alt="FILE - This handout file photo taken Sept. 2, 2014, provided by National Institute of Allergy and Infectious Diseases (NIAID) shows a 39-year-old woman, the first participant enrolled in VRC 207, receiving a dose of the investigational NIAID/GSK Ebola vaccine at the National Institute of Health (NIH) Clinical Center in Bethesda, Md. The hope is that the first human safety study of the vaccine might eventually be used in the current Ebola outbreak in West Africa. New monkey studies show that one shot of an experimental Ebola vaccine can trigger fast protection, but the effect waned unless the animals got a booster shot made a different way. (AP Photo/NIAID, File)" align="left" title="FILE - This handout file photo taken Sept. 2, 2014, provided by National Institute of Allergy and Infectious Diseases (NIAID) shows a 39-year-old woman, the first participant enrolled in VRC 207, receiving a dose of the investigational NIAID/GSK Ebola vaccine at the National Institute of Health (NIH) Clinical Center in Bethesda, Md. The hope is that the first human safety study of the vaccine might eventually be used in the current Ebola outbreak in West Africa. New monkey studies show that one shot of an experimental Ebola vaccine can trigger fast protection, but the effect waned unless the animals got a booster shot made a different way. (AP Photo/NIAID, File)" border="0" /></a>By Sharon Begley NEW YORK (Reuters) - An experimental Ebola vaccine similar to one being developed by GlaxoSmithKline is effective for at least five weeks in lab monkeys but requires boosting with an additional vaccine to extend its protection to 10 months, according to a study published on Sunday. The findings offer an early hint of which, if any, of the Ebola vaccines in development will prove effective, and in what form. Johnson &amp; Johnson and NewLink Genetics are also among the firms accelerating their efforts to provide Ebola vaccines and treatments as the worst known outbreak of the virus ravages West Africa, killing more than 2,000 people. The results of the new study suggest, for instance, that a GSK vaccine now being tested on healthy volunteers will protect against Ebola infection in the short term, but may have to be augmented for long-term protection.</p><br clear="all"/>

Source: You are not allowed to view links. Register or Login